Barclays raised the firm’s price target on Boston Scientific (BSX) to $136 from $133 and keeps an Overweight rating on the shares. The company issued an “impressive” three-year plan with organic growth of 10%, driving by a broad array of growth programs, the analyst tells investors in a research note. The firm sees “significant upside” for Boston Scientific shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Top 3 Trending Stocks, According to Analysts – 10/1/2025
- Boston Scientific call volume above normal and directionally bullish
- Boston Scientific price target raised to $129 from $125 at Truist
- Elutia closes sale of its BioEnvelope business to Boston Scientific for $88M
- Boston Scientific price target raised to $132 from $127 at BTIG